Flavored tobacco products lure people to start smoking and influences them to continue with the habit of smoking, a study showed.
In a survey of 10,030 people from 13 to 39 years of age conducted by Kim Hee-jin, a professor at Yonsei University Graduate School of Public Health, it was found that 77.2 percent of 5,243 smokers used flavored cigarettes, up over 12 percent from 2016.
By gender, the flavored tobacco usage rate stood at 75.9 percent for men and 78.4 percent for women.
Sixty-seven percent of those who had smoking experience said that flavored tobacco exerted influence on their first try.
The primary reason given for using flavored tobacco products was ‘taste.’
Those who started smoking with flavored cigarettes were 1.4 times more likely to continue smoking than others those who started with non-flavored tobacco.
The probability that they would continue smoking with flavored tobacco was 10.9 times higher.


Oil Prices Surge Amid Middle East Tensions as Global Markets React Cautiously
US-Iran Peace Talks Fuel Market Optimism Amid Ongoing Tensions
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Is dark chocolate healthier than milk chocolate? 2 dietitians explain
The Beauty Beneath the Expressway: A Journey from Self to Service
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
US Dollar Slips Amid Iran Tensions and Fed Leadership Uncertainty
Disaster or digital spectacle? The dangers of using floods to create social media content
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 



